Compare WFF & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFF | PASG |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Malaysia | United States |
| Employees | N/A | 27 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9M | 14.6M |
| IPO Year | 2024 | 2020 |
| Metric | WFF | PASG |
|---|---|---|
| Price | $0.11 | $3.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 19.3M | 19.9K |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $3.29 |
| 52 Week High | $50.60 | $20.00 |
| Indicator | WFF | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 43.53 | 35.96 |
| Support Level | N/A | $3.29 |
| Resistance Level | $2.04 | $5.04 |
| Average True Range (ATR) | 5.63 | 0.39 |
| MACD | -0.42 | -0.07 |
| Stochastic Oscillator | 0.01 | 7.95 |
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings, and other custom-made FRP products. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance. Geographically, the company generates the majority of its revenue from Australia.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.